Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Innovent Biologics' Clinical Study: Innovent Biologics has initiated a Phase 2 clinical study for efdamrofusp alfa, a bispecific fusion protein aimed at treating diabetic macular edema (DME), with the first patient dosing completed. The study will evaluate the drug's efficacy and safety compared to the current standard treatment, Faricimab.

Impact of Diabetic Macular Edema: DME is a significant cause of vision impairment among the diabetic population in China, affecting an estimated 4 to 5 million patients due to complications from diabetes. The study aims to address unmet medical needs related to frequent injections and long-term treatment efficacy.